The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Open accessAbstract
Promising preclinical activity with agents blocking the function of vascular endothelial growth factor (VEGF) has been observed in various cancer types, especially with combination therapy. However, these drugs decrease microvessel density, and it is not known whether this reduced vessel density (VD) results in decreased delivery of concomitantly administered classical anticancer drugs. We designed an in vivo study to investigate the relation between VEGF-blocking therapy, tumoral blood vessels, and intratumoral uptake of anticancer drugs. Nude NMRI mice bearing colon adenocarcinoma (HT29) were treated with the anti-VEGFmAb A4.6.1 or placebo. After 1 week, CPT-11 was administered 1 h prior to killing the animals. In A4.6.1 treated tumours, there was a significant decrease in VD, more pronounced with potentially functional large vessels than endothelial cords. Interestingly, a trend to increased intratumoral CPT-11 concentration was observed (P=0.09). In parallel, we measured an increase in tumour perfusion, as estimated by high-performance liquid chromatography determination of intratumoural Hoechst 33342 concentration. In the growth delay study, CPT-11 was at least equally effective with or without pretreatment with A4.6.1. These data suggest that tumour vascular function and tumour uptake of anticancer drugs improve with VEGF-blocking therapy, and indicate the relevance for further investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Determination of subcutaneous tumor size in athymic (nude) mice
Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830 · cited 1×
“Three orthogonal diameters were measured with vernier callipers, and used to calculate the volume of the tumour using the formula a b c p/6 (Tomayko and Reynolds, 1989).”
MethodBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 947
(1990) · PubMed · Cited by 757
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Lee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 677
(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
The next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Leunig, M., Yuan, F., Menger, M. D., Boucher, Y., Goetz, A. E., Meßmer, K., & Jain, R. K. (1992) · PubMed · Cited by 370
Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis.
Kumar, S., Ghellal, A., Li, C., Byrne, G. J., Haboubi, N. Y., Wang, J. M., & Bundred, N. J. (1999) · PubMed · Cited by 361
Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
UKCCCR guidelines for the welfare of animals in experimental neoplasia
(1988) · Laboratory Animals · doi:10.1258/002367788780746467 · Cited by 308
Kozin, S. V., Boucher, Y., Hicklin, D. J., Böhlen, P., Jain, R. K., & Suit, H. D. (2001) · PubMed · Cited by 291
Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
KANEDA, N., Nagata, H., Furuta, T., & YOKOKURA, T. (1990) · PubMed · Cited by 291
Clinical Pharmacokinetics of Irinotecan
Chabot, G. G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733040-00001 · Cited by 282
Expression of the Endothelial Markers PECAM-1, vWf, and CD34 in Vivo and in Vitro
Müller, A. M., Hermanns, M. I., Skrzynski, C., Nesslinger, M., Müller, K.-M., & Kirkpatrick, C. J. (2002) · Experimental and Molecular Pathology · doi:10.1006/exmp.2002.2424 · Cited by 277
Baish, J. W., Gazit, Y., Berk, D. A., Nozue, M., Baxter, L. T., & Jain, R. K. (1996) · Microvascular Research · doi:10.1006/mvre.1996.0031 · Cited by 274
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00027-6 · Cited by 271
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher, B. A., Sotomayor, E. A., & Huang, Z. D. (1992) · PubMed · Cited by 260
Gerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 251
Borgström, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1998) · The Prostate · Cited by 248
Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents
Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y., & Brem, H. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570624 · Cited by 231
Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules
Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstead, D., Graham, W., Hunter, G. J., Wolf, G. L., Fischman, A., Boucher, Y., & Jain, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3137 · Cited by 202
Delivery of Molecular and Cellular Medicine to Solid Tumors
Jain, R. K. (1997) · Microcirculation · doi:10.3109/10739689709148314 · Cited by 198
Fonsatti, E., Vecchio, L. D., Altomonte, M., Sigalotti, L., Nicotra, M. R., Coral, S., Natali, P. G., & Maio, M. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1095 · Cited by 173
Ljungkvist, A. S. E., Bussink, J., Rijken, P. F. J. W., Kaanders, J. H. A. M., van der Kogel, A. J., & Denekamp, J. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02938-3 · Cited by 144
Logothetis, C. J., Wu, K. K., Finn, L. D., Daliani, D., Figg, W. D., Ghaddar, H. M., & Gutterman, J. U. (2001) · PubMed · Cited by 140
A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Bhargava, P., Marshall, J. L., Rizvi, N. A., Dahut, W., Yoe, J., Figuera, M., Phipps, K., Ong, V. S., Kato, A., & Hawkins, M. (1999) · PubMed · Cited by 136
Fonsatti, E., Jekunen, A. P., Kairemo, K., et al. (2000) · PubMed · Cited by 135
Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma
Stadler, W. M., Kuzel, T. M., Shapiro, C. M., Sosman, J. A., Clark, J. I., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2541 · Cited by 123
Estimators of the number of objects per area unbiased by edge effects.
Hj, G. (1978) · PubMed · Cited by 123
Teicher, B. A., Holden, S. A., Ara, G., Dupuis, N. P., Liu, F., Yuan, J., Ikebe, M., & Kakeji, Y. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610523 · Cited by 121
Vajkoczy, P., Schilling, L., Ullrich, A., Schmiedek, P., & Menger, M. D. (1998) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199805000-00006 · Cited by 120
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours
Smith, K., Hill, S., Begg, A. C., & Denekamp, J. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.54 · Cited by 112
Gee, M. S., Saunders, H., Lee, J. C., Sanzo, J. F., Jenkins, W. T., Evans, S. M., Trinchieri, G., Sehgal, C. M., Feldman, M. D., & Lee, W. M. F. (2001) · PubMed · Cited by 110
Rowe, D. H., Huang, J., Kayton, M. L., Thompson, R., Troxel, A. B., O’Toole, K., Yamashiro, D. J., Stolar, C. J. H., & Kandel, J. J. (2000) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(00)80008-1 · Cited by 109
Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours
Chaplin, D. J., & Hill, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.235 · Cited by 106
Intravital Fluorescence Videomicroscopy to Study Tumor Angiogenesis and Microcirculation
Vajkoczy, P., Ullrich, A., & Menger, M. D. (2000) · Neoplasia · doi:10.1038/sj.neo.7900062 · Cited by 101
O'Leary, J. J., Shapiro, R. L., Ren, C. J., Chuang, N., Cohen, H. W., & Potmĕsil, M. (1999) · PubMed · Cited by 96
Bussink, J., Kaanders, J. H. A. M., Rijken, P. F. J. W., Raleigh, J. A., & van der Kogel, A. J. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0398:cibpah]2.0.co;2 · Cited by 95
Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice
Beecken, W.-D., Fernandez, A., Joussen, A. M., Achilles, E. G., Flynn, E., Lo, K.-M., Gillies, S. D., Javaherian, K., Folkman, J., & Shing, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.5.382 · Cited by 89
pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
Kobayashi, K., Bouscarel, B. E., Matsuzaki, Y., Ceryak, S. M., Kudoh, S., & Fromm, H. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991112)83:4<491::aid-ijc10>3.0.co;2-m · Cited by 72
Role of organelle pH in tumor cell biology and drug resistance
Simon, S. M. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01276-8 · Cited by 67
In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood
Combes, O., Barré, J., Duché, J.-C., Vernillet, L., Archimbaud, Y., Marietta, M. P., Tillement, J. P., & Urien, S. (2000) · Investigational New Drugs · doi:10.1023/a:1006379730137 · Cited by 63
Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle, F., Bissery, M.-C., André, S., Roquet, F., & Riou, J. (1996) · PubMed · Cited by 62
Inhibition of Angiogenesis Induces Chromaffin Differentiation and Apoptosis in Neuroblastoma
Wassberg, E., Hedborg, F., Sköldenberg, E. G., Stridsberg, M., & Christofferson, R. H. B. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65286-8 · Cited by 61
Teicher, B. A., Dupuis, N. P., Robinson, M., Emi, Y., & Goff, D. A. (1995) · PubMed · Cited by 61
Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo
Soh, E. Y., Eigelberger, M. S., Kim, K. J., Wong, M. G., Young, D. M., Clark, O. H., & Duh, Q. (2000) · Surgery · doi:10.1067/msy.2000.110430 · Cited by 56
Bernsen, H. J. J. A., Rijken, P. F. J. W., Hagemeier, N. E. M., & van der Kogel, A. J. (1999) · Microvascular Research · doi:10.1006/mvre.1999.2143 · Cited by 41
Kamiya, K., Konno, H., Tanaka, T., Baba, M., Matsumoto, K., Sakaguchi, T., Yukita, A., Asano, M., Suzuki, H., Arai, T., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00817.x · Cited by 33
Thomas, C. D., Stern, S., Chaplin, D. J., & Guichard, M. (1996) · Radiotherapy and Oncology · doi:10.1016/0167-8140(96)01734-3 · Cited by 18
Wildiers, H. P. M. W., Guetens, G., Boeck, G. D., Landuyt, W., Verbeken, E. K., Highley, M., de Bruijn, E. A., & van Oosterom, A. T. (2002) · International Journal of Cancer · doi:10.1002/ijc.10391 · Cited by 13
Self-citation
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Metadata
- Authors
- Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T.
- Venue
- British Journal of Cancer
- Published
- 2003-06
- Volume
- 88
- Issue
- 12
- Pages
- 1979-1986
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2069496194
- Cited by
- 334
- References
- 63
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.